{"created":"2021-10-26T05:15:40.939769+00:00","id":2001688,"links":{},"metadata":{"_buckets":{"deposit":"cadd1dd3-f356-49a9-b7ea-e84df124572c"},"_deposit":{"created_by":25,"id":"2001688","owner":"25","owners":[25],"owners_ext":{"displayname":"wataka","username":"kuma1008"},"pid":{"revision_id":0,"type":"depid","value":"2001688"},"status":"published"},"_oai":{"id":"oai:tsukuba.repo.nii.ac.jp:02001688","sets":["2780:2206","3:62:5588:1635225066520"]},"author_link":["695"],"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"10","bibliographicPageEnd":"516","bibliographicPageStart":"507","bibliographicVolumeNumber":"16","bibliographic_titles":[{"bibliographic_title":"Future Oncology","bibliographic_titleLang":"en"}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Nonmuscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high rates of disease recurrence and progression. Current treatment for high-risk NMIBC involves Bacillus Calmette-Guérin (BCG) therapy, but treatment options are limited for patients with recurrent or BCG-unresponsive disease. Aberrant programmed death 1 signaling has been implicated in BCG resistance and bladder cancer recurrence and progression, and pembrolizumab has shown efficacy in patients with BCG-unresponsive high-risk NMIBC. Aim: To describe the rationale and design for the randomized, comparator-controlled Phase III KEYNOTE-676 study, which will evaluate the efficacy and safety of pembrolizumab in combination with BCG in patients with persistent/recurrent high-risk NMIBC after BCG induction therapy.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_5_publisher_27":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Future Medicine","subitem_publisher_language":"en"}]},"item_5_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"32162533","subitem_relation_type_select":"PMID"}}]},"item_5_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.2217/fon-2019-0817","subitem_relation_type_select":"DOI"}}]},"item_5_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/","subitem_rights_language":"en"}]},"item_5_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1479-6694","subitem_source_identifier_type":"PISSN"}]},"item_5_source_id_9":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA1206226X","subitem_source_identifier_type":"NCID"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kamat, Ashish M","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Shore, Neal","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hahn, Noah","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Alanee, Shaheen","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"西山, 博之","creatorNameLang":"ja"},{"creatorName":"ニシヤマ, ヒロユキ","creatorNameLang":"ja-Kana"},{"creatorName":"NISHIYAMA, Hiroyuki","creatorNameLang":"en"}],"familyNames":[{},{},{}],"givenNames":[{},{},{}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Shariat, Shahrokh","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nam, Kijoeng","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kapadia, Ekta","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Frenkl, Tara","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Steinberg, Gary","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-10-26"}],"displaytype":"detail","filename":"FO_16-10.pdf","filesize":[{"value":"1.5 MB"}],"format":"application/pdf","licensetype":"license_5","url":{"objectType":"fulltext","url":"https://tsukuba.repo.nii.ac.jp/record/2001688/files/FO_16-10.pdf"},"version_id":"3d21e617-54bd-4146-9726-5b155d1267b9"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC","subitem_title_language":"en"}]},"item_type_id":"5","owner":"25","path":["2206","1635225066520"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-10-26"},"publish_date":"2021-10-26","publish_status":"0","recid":"2001688","relation_version_is_last":true,"title":["KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2022-04-27T09:52:30.020617+00:00"}